Structure Therapeutics (NASDAQ:GPCR – Get Free Report) and Liquidia (NASDAQ:LQDA – Get Free Report) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.
Profitability
This table compares Structure Therapeutics and Liquidia’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Structure Therapeutics | N/A | -24.91% | -23.67% |
| Liquidia | 7.74% | 46.82% | 7.06% |
Volatility & Risk
Structure Therapeutics has a beta of -1.5, meaning that its share price is 250% less volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Structure Therapeutics | N/A | N/A | -$141.20 million | ($0.87) | -59.36 |
| Liquidia | $158.32 million | 40.00 | -$68.92 million | $0.14 | 508.64 |
Liquidia has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Structure Therapeutics and Liquidia, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Structure Therapeutics | 2 | 1 | 12 | 3 | 2.89 |
| Liquidia | 2 | 1 | 5 | 3 | 2.82 |
Structure Therapeutics currently has a consensus price target of $110.55, suggesting a potential upside of 114.07%. Liquidia has a consensus price target of $68.88, suggesting a potential downside of 3.28%. Given Structure Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Structure Therapeutics is more favorable than Liquidia.
Insider and Institutional Ownership
91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by insiders. Comparatively, 25.6% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Liquidia beats Structure Therapeutics on 9 of the 13 factors compared between the two stocks.
About Structure Therapeutics
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
About Liquidia
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
